Tebokan Mechanism of Action

Pharmacology: Properties: Based on a complicated patented manufacturing process, Ginkgo biloba EGb 761 (Tebokan) contains enriched active ingredients obtained from leaves of the Ginkgo tree. Ginkgo biloba EGb 761 (Tebokan) improves the flow properties of the blood and increases its flow rate, particularly the region of small and very small blood vessel. Both in the brain as well as in the arms and legs. Ginkgo biloba EGb 761 (Tebokan) produces an improvement in the supply of blood and oxygen to the tissue, and protects tissue cells from the damaging effects of lack in oxygen.
In case of disturbances of cerebral performance, Ginkgo biloba EGb 761 (Tebokan) improves decreasing intellectual capacity and vigilance, thus providing relief to accompanying symptoms such as dizziness, tinnitus, headache, deficient memory and emotional instability with anxiety.
Ginkgo biloba EGb 761 (Tebokan) increases hearing capacity in case of cervical syndrome.
Ginkgo biloba EGb 761 (Tebokan) produces a reduction in pain and unpleasant sensations with formication as well as a sensation of numbness and coldness accompanying circulatory disturbances in the limbs. In the case of intermittent claudication (walking pains) Ginkgo biloba EGb 761 (Tebokan) clearly extends the painfree walking distance. Ginkgo biloba EGb 761 (Tebokan) has no unfavorable influence on the carbohydrate metabolism and is therefore also suitable for diabetics.
Pharmacodyamics: The following pharmacological effects have been proven in animal experiments with the quantified extract of EGb 761 contained in Tebokan: Increased in tolerance to hypoxia, in particular of the cerebral tissue, inhibition of the development of traumatically or toxically induced brain edema and acceleration of its regression, reduction of retina edema and lesions of retina cells, inhibition of age-related reduction of muscarinergic choline receptors and alpha-2-adrenoceptors as well as promotion of choline intake in the hippocampus, enhancement of memory performance and learning capacity, improved compensation of disturbances of equilibrium, circulatory increase in particular in the region of microcirculation, improvement of rheological properties of the blood, inactivation of toxic oxygen radicals (flavonoids), PAF antagonism (ginkgolides) and neuroprotective effect (ginkgolides A and B, bilobalide).
Hypoxia-protective effects, increase of blood flow, in particular in the microcirculatory region and improvement of the rheological properties of the blood could be demonstrated in humans.
Pharmacokinetics: Cerebral bioavailability of the quantified extract EGb 761 in humans was demonstrated in the pharmaco-EEG on the base of dose-dependent effects on cerebro-electrical activity.
After oral application of 80mg Ginkgo extract, the terpene lactone ginkgolide A, ginkgolide B and bilobalide showed in humans a very good absolute bioavailability of 98% for ginkgolide A, 79% for ginkgolide B and 72% for bilobalide. Maximum plasma concentrations were 15 ng/ml for ginkgolide A, 4 ng/ml for ginkgolide B and approx. 12 ng/ml for bilobalide. Half-lives were 3.9 hours (ginkgolide A), 7 hours (ginkgolide B) and 3.2 hours (bilobalide).
Plasma-protein binding (human blood) is 43% for ginkgolide A, 47% for ginkgolide B and 67% for bilobalide.
In the rat, resorption rate of 60% was determined following oral administration of 14C radioactively tagged extract EGb 761. Maximum plasma concentrations were measured 1.5 hours after administration; half-life was 4.5 hours. A second plasma peak 12 hours after administration is indicative of an enterohepatic shunt.